Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
I
t is impossible to protect whole nations from the effects of bioterrorism by preventive vaccination. There are too many possible
agents, the costs would be exorbitantly high, and the health risks associated with complex mass vaccination programs would be
unacceptable for the public health authorities. Adequate protection, however, could be provided via a combination of rapid detection
and diagnosis with proper treatment for those exposed to biological weapon agents. Preferably this should be done with therapeutics,
which would be beneficial in all stages of infection to disease. Monoclonal antibodies, preferably from human origin, can be used
to prevent severe complications by neutralizing or blocking the pathological elements of biological agents and these are the optimal
candidates to be deployed in case of biological warfare or a bioterrorist event. Recent research in aerosol challenged rabbits has shown
that the application of a combination of a human monoclonal antibody against the protective antigen (PA) and one against the lethal
factor (LF) of the anthrax toxin is highly efficacious even when given 48 hours after the exposure. In this models, all animals are
symptomatic around 30 hrs after exposure and all exposed but untreated rabbits have died around 90 hrs after exposure. This new
development offers a safe and effective therapy, which could save lives even days after the bioterror victims have been infected with
anthrax spores. The human body is one of the better, and most suitably equipped places for the generation of monoclonal antibodies,
intended for effective treatment of humans. Such antibodies will be optimal in specificity, affinity, in functional and pharmacological
properties. In addition, the chances on adverse effects and cross-reactivity with human tissues will be minimal. For these reasons, the
human immune response is used as a basis for the selection and generation of antibodies by the Dutch company IQ Therapeutics in
Groningen, in close cooperation with the US Naval Medical Research Center and financially supported by the Dutch Armed Forces
and the US Defense Threat Reduction Agency,. Persons, immunised against or infected with an agent of interest, donate blood cells in
this research program voluntarily. This blood is used to select the white blood cells producing the antibodies of interest. Those cells are
the basis of the fully human monoclonal antibodies generated with IQ?s Cloning the Human Response? technology.
Biography
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals